# Fulvestrant Versus Fulvestrant Plus Palbociclib in Operable Breast Cancer Responding to Fulvestrant

> **NCT03447132** · PHASE3 · COMPLETED · sponsor: **International Cancer Research Group, United Arab Emirates** · enrollment: 354 (actual)

## Conditions studied

- Breast Neoplasm Female

## Interventions

- **DRUG:** Fulvestrant 500mg
- **DRUG:** Palbociclib 125mg
- **DRUG:** Goserelin 3.6 MG
- **DRUG:** Placebos

## Key facts

- **NCT ID:** NCT03447132
- **Lead sponsor:** International Cancer Research Group, United Arab Emirates
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-20
- **Primary completion:** 2021-04-12
- **Final completion:** 2021-07-20
- **Target enrollment:** 354 (ACTUAL)
- **Last updated:** 2023-03-10

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03447132

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03447132, "Fulvestrant Versus Fulvestrant Plus Palbociclib in Operable Breast Cancer Responding to Fulvestrant". Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/clinical/NCT03447132. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*